Literature DB >> 27174493

How many cycles of 7+3 and for whom?

Y Ofran1,2, J M Rowe1,2,3.   

Abstract

Mesh：

Year:  2016        PMID： 27174493     DOI： 10.1038/leu.2016.86

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.

Authors:  Jacob M Rowe; Haesook T Kim; Peter A Cassileth; Hillard M Lazarus; Mark R Litzow; Peter H Wiernik; Martin S Tallman
Journal:  Cancer       Date:  2010-11-01       Impact factor: 6.860

2.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

3.  Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.

Authors:  Yishai Ofran; Ronit Leiba; Chezi Ganzel; Revital Saban; Moshe Gatt; Ron Ram; Ariela Arad; Shlomo Bulvik; Ilana Hellmann; Sharon Gino-Moor; Tsila Zuckerman; Ron Hoffman; Netanel Horowitz; Noa Lavi; Shimrit Ringelstein; Israel Henig; Michal Hayun; Jacob M Rowe
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

4.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

Authors:  Fumihiko Ishikawa; Shuro Yoshida; Yoriko Saito; Atsushi Hijikata; Hiroshi Kitamura; Satoshi Tanaka; Ryu Nakamura; Toru Tanaka; Hiroko Tomiyama; Noriyuki Saito; Mitsuhiro Fukata; Toshihiro Miyamoto; Bonnie Lyons; Koichi Ohshima; Naoyuki Uchida; Shuichi Taniguchi; Osamu Ohara; Koichi Akashi; Mine Harada; Leonard D Shultz
Journal:  Nat Biotechnol       Date:  2007-10-21       Impact factor: 54.908

5.  Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Authors:  Jeffery M Klco; Christopher A Miller; Malachi Griffith; Allegra Petti; David H Spencer; Shamika Ketkar-Kulkarni; Lukas D Wartman; Matthew Christopher; Tamara L Lamprecht; Nicole M Helton; Eric J Duncavage; Jacqueline E Payton; Jack Baty; Sharon E Heath; Obi L Griffith; Dong Shen; Jasreet Hundal; Gue Su Chang; Robert Fulton; Michelle O'Laughlin; Catrina Fronick; Vincent Magrini; Ryan T Demeter; David E Larson; Shashikant Kulkarni; Bradley A Ozenberger; John S Welch; Matthew J Walter; Timothy A Graubert; Peter Westervelt; Jerald P Radich; Daniel C Link; Elaine R Mardis; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  JAMA       Date:  2015-08-25       Impact factor: 56.272

6.  Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.

Authors:  T Köhnke; D Sauter; K Ringel; E Hoster; R P Laubender; M Hubmann; S K Bohlander; P M Kakadia; S Schneider; A Dufour; M-C Sauerland; W E Berdel; T Büchner; B Wörmann; J Braess; W Hiddemann; K Spiekermann; M Subklewe
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528

7.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Authors:  Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Christina Sauerland; Wolfgang Berdel; Thomas Buchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

8.  Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.

Authors:  Sarah Bertoli; Pierre Bories; Marie C Béné; Sylvie Daliphard; Bruno Lioure; Arnaud Pigneux; Norbert Vey; Jacques Delaunay; Vincent Leymarie; Isabelle Luquet; Odile Blanchet; Pascale Cornillet-Lefebvre; Mathilde Hunault; Didier Bouscary; Nathalie Fegueux; Philippe Guardiola; François Dreyfus; Jean Luc Harousseau; Jean Yves Cahn; Norbert Ifrah; Christian Récher
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

9.  Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

Authors:  M Othus; S Mukherjee; M A Sekeres; J Godwin; S Petersdorf; F R Appelbaum; H Erba; E Estey
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528
  9 in total
  1 in total

1.  Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy.

Authors:  Branson Chen; Jong Bok Lee; Hyeonjeong Kang; Mark D Minden; Li Zhang
Journal:  J Exp Clin Cancer Res       Date:  2018-04-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.